Literature DB >> 11937556

CD8+ T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major.

Yasmine Belkaid1, Esther Von Stebut, Susana Mendez, Rosalia Lira, Elisabet Caler, Sylvie Bertholet, Mark C Udey, David Sacks.   

Abstract

Standard murine models of cutaneous leishmaniasis, involving s.c. inoculation of large numbers of Leishmania major promastigotes, have not supported an essential role for CD8(+) T cells in the control of primary infection. Recently, a L. major model combining two main features of natural transmission, low parasite dose and inoculation into a dermal site, has been established in resistant C57BL/6 mice. In the present studies, C57BL/6 mice with CD8(+) T cell deficiencies, including CD8(-/-) and CD8-depleted mice, failed to control the growth of L. major following inoculation of 100 metacyclic promastigotes into the ear dermis. The resulting dermal pathology was minor and delayed. Lesion formation in wild-type mice was coincident with the killing of parasites in the inoculation site. Both events were associated with the accumulation of CD8(+) T lymphocytes in the skin and with the capacity of CD8(+) T cells recovered from draining lymph nodes or infected dermis to release IFN-gamma following coculture with infected dendritic cells. Reconstitution of resistance to L. major in RAG(-/-) mice using T cells from naive donors was optimal when both CD4(+) and CD8(+) T cells were transferred. Primed CD8(+) T lymphocytes obtained from C57BL/6 mice during the acute stage of infection were able to mediate both pathology and immunity when transferred alone. The low dose, intradermal challenge model reveals that CD8(+) T cells play an essential role in both pathogenesis of and immunity to primary infection with L. major in the skin.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11937556     DOI: 10.4049/jimmunol.168.8.3992

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  118 in total

Review 1.  Leishmaniasis: new approaches to disease control.

Authors:  Clive R Davies; Paul Kaye; Simon L Croft; Shyam Sundar
Journal:  BMJ       Date:  2003-02-15

2.  Killer lymphocytes use granulysin, perforin and granzymes to kill intracellular parasites.

Authors:  Farokh Dotiwala; Sachin Mulik; Rafael B Polidoro; James A Ansara; Barbara A Burleigh; Michael Walch; Ricardo T Gazzinelli; Judy Lieberman
Journal:  Nat Med       Date:  2016-01-11       Impact factor: 53.440

3.  Toward a novel experimental model of infection to study American cutaneous leishmaniasis caused by Leishmania braziliensis.

Authors:  Tatiana R de Moura; Fernanda O Novais; Fabiano Oliveira; Jorge Clarêncio; Almério Noronha; Aldina Barral; Claudia Brodskyn; Camila I de Oliveira
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

4.  Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice.

Authors:  Salvador Iborra; Javier Carrión; Charles Anderson; Carlos Alonso; David Sacks; Manuel Soto
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

5.  Leishmania major attenuates host immunity by stimulating local indoleamine 2,3-dioxygenase expression.

Authors:  Levi H C Makala; Babak Baban; Henrique Lemos; Ahmed R El-Awady; Phillip R Chandler; De-Yan Hou; David H Munn; Andrew L Mellor
Journal:  J Infect Dis       Date:  2011-01-31       Impact factor: 5.226

6.  Leishmania infantum sterol 24-c-methyltransferase formulated with MPL-SE induces cross-protection against L. major infection.

Authors:  Yasuyuki Goto; Ajay Bhatia; Vanitha S Raman; Silvia E Z Vidal; Sylvie Bertholet; Rhea N Coler; Randall F Howard; Steven G Reed
Journal:  Vaccine       Date:  2009-03-09       Impact factor: 3.641

7.  Activation outcomes induced in naïve CD8 T-cells by macrophages primed via "phagocytic" and nonphagocytic pathways.

Authors:  Isabel María Olazabal; Noa Beatriz Martín-Cofreces; María Mittelbrunn; Gloria Martínez del Hoyo; Balbino Alarcón; Francisco Sánchez-Madrid
Journal:  Mol Biol Cell       Date:  2007-12-12       Impact factor: 4.138

8.  Protective immunization against visceral leishmaniasis using Leishmania sterol 24-c-methyltransferase formulated in adjuvant.

Authors:  Yasuyuki Goto; Lisa Y Bogatzki; Sylvie Bertholet; Rhea N Coler; Steven G Reed
Journal:  Vaccine       Date:  2007-08-20       Impact factor: 3.641

9.  Immunologic Markers of Protection in Leishmania (Viannia) braziliensis Infection: A 5-Year Cohort Study.

Authors:  Aline C Muniz; Olívia Bacellar; Ednaldo Lima Lago; Augusto M Carvalho; Pedro Paulo Carneiro; Luiz Henrique Guimarães; Paulo N Rocha; Lucas P Carvalho; Marshall Glesby; Edgar M Carvalho
Journal:  J Infect Dis       Date:  2016-05-18       Impact factor: 5.226

10.  Coinjection with CpG-containing immunostimulatory oligodeoxynucleotides reduces the pathogenicity of a live vaccine against cutaneous Leishmaniasis but maintains its potency and durability.

Authors:  Susana Mendez; Khaled Tabbara; Yasmine Belkaid; Sylvie Bertholet; Daniela Verthelyi; Dennis Klinman; Robert A Seder; David L Sacks
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.